Literature DB >> 29125071

Clinical experience in idiopathic pulmonary fibrosis: a retrospective study.

Julien Guiot1, Bernard Duysinx1, Laurence Seidel2, Monique Henket1, Fanny Gester1, Olivier Bonhomme1, Jean-Louis Corhay1, Renaud Louis1.   

Abstract

Introduction Idiopathic pulmonary fibrosis (IPF) is a rare lung disease with an increased incidence since the last few years. Here, we report our eight-year clinical experience in CHU of Liège, Belgium. Methods We have studied retrospectively patients recruited from our ambulatory care polyclinic at CHU of Liège from 1 January 2009 to 1 January 2017. We have excluded all patients treated with a specific anti-fibrotic therapy due to incomplete follow-up. The diagnosis of IPF was made according to the ATS/ERS international recommendations (2015). Results Out of the 114 patients initially selected, 82 cases were found to be suitable for the analysis. The average age was 71.1 ± 9.35 years with a male predominance. The median survival was 43.7 months (23.6-71.7) with a majority (45%) of patients in the group II of the GAP index. The median rate of annual decline in diffusion capacity of CO (DLCO) was 11%, whereas the sub analysis for group III (according to GAP index) showed a decrease annual rate of 30%. Conclusion Our results are in keeping with the literature. One of our major finding is that patients in GAP III exhibit an annual rate of mortality of 42% and a median annual decline in DLCO of 30%. This observation highlights the fact that this specific subgroup of patients presents a high risk of morbi-mortality.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; interstitial lung diseases; prognosis

Mesh:

Year:  2017        PMID: 29125071     DOI: 10.1080/17843286.2017.1399228

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  5 in total

Review 1.  Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets.

Authors:  Julien Guiot; Ingrid Struman; Edouard Louis; Renaud Louis; Michel Malaise; Makon-Sébastien Njock
Journal:  J Clin Med       Date:  2019-08-29       Impact factor: 4.241

Review 2.  Exosomal Long Non-Coding RNAs in Lung Diseases.

Authors:  Christophe Poulet; Makon-Sébastien Njock; Catherine Moermans; Edouard Louis; Renaud Louis; Michel Malaise; Julien Guiot
Journal:  Int J Mol Sci       Date:  2020-05-19       Impact factor: 5.923

Review 3.  Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Authors:  Qiang Zheng; Ingrid A Cox; Julie A Campbell; Qing Xia; Petr Otahal; Barbara de Graaff; Tamera J Corte; Alan K Y Teoh; E Haydn Walters; Andrew J Palmer
Journal:  ERJ Open Res       Date:  2022-03-14

4.  Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ?

Authors:  Julien Guiot; Monique Henket; Anne-Noëlle Frix; Fanny Gester; Marie Thys; Laurie Giltay; Colin Desir; Catherine Moermans; Makon-Sébastien Njock; Paul Meunier; Jean-Louis Corhay; Renaud Louis
Journal:  Respir Res       Date:  2022-04-11

5.  Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p.

Authors:  Ingrid Struman; Makon-Sébastien Njock; Julien Guiot; Maureen Cambier; Amandine Boeckx; Monique Henket; Olivier Nivelles; Fanny Gester; Edouard Louis; Michel Malaise; Franck Dequiedt; Renaud Louis
Journal:  Thorax       Date:  2020-08-05       Impact factor: 9.139

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.